The original disclosure in Japanese was released on February 10, 2021 at 15:30 (GMT+9)

Consolidated Financial Statements for the Third Quarter Ended December 31, 2020
FY2021 (April 1, 2020 - March 31, 2021) [UNAUDITED]

Company name: Takara Holdings Inc.
Stock exchange listings: Tokyo Stock Exchange (1st section)
Code number: 2531
URL: https://www.takara.co.jp/
Company representative: Mutsumi Kimura, President
Contact: Masakazu Usami, General Manager of Financial & Investor Relations Dept.
TEL : (075)241-5124
Quarterly statement filing date (as planned): February 12, 2021

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

1. Results for the nine months ended December 31, 2020 (April 1, 2020 - December 31, 2020)

(1) Consolidated operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Nine months ended December 31, 2020		Nine months ended December 31, 2019	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	206,938	(2.5)	212,172	0.7
Operating income (loss)	17,186	33.9	12,836	(14.5)
Ordinary income (loss)	17,568	32.2	13,290	(13.8)
Net income (loss) attributable to owners of the parent	9,268	11.7	8,300	(7.3)
Net income (loss) per share (Yen)	46.88		41.61	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income (loss)	11,083	73.0	6,406	(5.9)

(2) Consolidated financial position

	As of December 31, 2020	As of March 31, 2020
	(Millions of yen)	(Millions of yen)
Total assets	306,726	283,882
Net assets	188,059	181,329
Equity ratio (%)	50.0	52.1
(Reference) Equity	153,303	147,762

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2020	Year ending March 31, 2021	Year ending March 31, 2021(Forecast)
First quarter end	-	-	
Second quarter end	-	-	
Third quarter end	-	-	
Year end	20.00		20.00
Annual	20.00		20.00

Note: Correction of dividend forecast from the most recent dividend forecast: No

3. Forecast for the year ending March 31, 2021 (April 1, 2020 - March 31, 2021)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ending March 31, 2021	
	(Millions of yen)	(%)
Net sales	277,000	(1.5)
Operating income (loss)	19,200	21.2
Ordinary income (loss)	19,300	18.6
Net income (loss) attributable to owners of the parent	9,700	8.0
Net income per share (Yen)	49.06	

Note: Correction of financial forecast from the most recent financial forecast: Yes

4. Others

(1) Material changes in subsidiaries during this period
(Changes in specified subsidiaries that caused a change in the scope of consolidation): No

(2) Accounting procedures specific to quarterly consolidated financial statements: No

(3) Changes in accounting policies, accounting estimates and retrospective restatement

1) Changes based on revisions of accounting standard: No

2) Changes other than ones based on revisions of accounting standard: No

3) Changes in accounting estimates: No

4) Restatement: No

(4) Number of outstanding shares (common stock)

1) Number of outstanding shares at the end of each period (Treasury stocks are included):

As of December 31, 2020	199,699,743 shares
As of March 31, 2020	199,699,743 shares

2) Number of treasury stocks at the end of each period:

As of December 31, 2020	1,995,450 shares
As of March 31, 2020	1,995,163 shares

3) Average number of outstanding shares in each period:

Nine months ended December 31, 2020	197,704,523 shares
Nine months ended December 31, 2019	199,495,658 shares

Contents of the attached document

1. Qualitative Information for the Nine Months Ended December 31, 2020 …… 2

(1) Consolidated Financial Results …… 2

(2) Consolidated Financial Position …… 3

(3) Qualitative Information Regarding Consolidated Forecasts …… 4

2. Consolidated Quarterly Financial Statements and Primary Notes …… 5

(1) Consolidated Balance Sheets …… 5

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income …… 7

(Consolidated Statements of Income) …… 7
(For the Nine Months Ended December 31, 2020 and 2019)

(Consolidated Statements of Comprehensive Income) …… 8
(For the Nine Months Ended December 31, 2020 and 2019)

(3) Notes on Consolidated Financial Statements …… 9

(Notes on Premise of Going Concern) …… 9

(Notes on Material Changes in Shareholders' Equity) …… 9

(Segment Information) …… 9

○ Supplement for the Consolidated Financial Statements

1. Qualitative Information for the Nine Months Ended December 31, 2020

(1) Consolidated Financial Results

In the nine months ended December 31, 2020, the Japanese economy continued to face a severe situation due to the prolonged effects of COVID-19. Overseas, the outlook of the economic trend remains uncertain, largely given the impacts of the prolonged trade friction between the U.S. and China and the Brexit (the U.K.'s withdrawal from the EU), compounded by worldwide prevalence of the COVID-19 pandemic.

Under these circumstances, the Group has endeavored at the Takara Group Medium-Term Management Plan for FY2021-2023 which serves as the first step in the Group's action plans cited in its long-term management vision, TaKaRa Group Challenge for the 100th, announced in May 2020, while placing utmost priority on preventing COVID-19 infections and stopping expansion of the pandemic. The Group has been focusing on forging solid footing towards achieving sustainable growth, both in and outside of Japan, and enhancing the Group's corporate value, while keeping a close eye on the impact of COVID-19, flexibly addressing environmental changes, appropriately allocating and investing management resources in areas that should be strengthened, and promoting efforts to rebuild business structures and global corporate functions that consistently generate various forms of value that enhance profitability.

As a result, in the nine months ended December 31, 2020, net sales were down 2.5% year on year to ¥206,938 million. Gross profit increased 5.1% year on year to ¥86,199 million. Operating income increased 33.9% year on year to ¥17,186 million, while ordinary income was up 32.2% year on year to ¥17,568 million. Net income attributable to owners of the parent increased 11.7% year on year to ¥9,268 million.

Results by business segment were as follows.

[Takara Shuzo]

In the nine months ended December 31, 2020, net sales varied widely from category to category as a result of continued sluggish demand for dining outside the home at eating and drinking establishments and other such entities and also due to so-called stay-at-home demand. For alcoholic beverages, sales of sake declined substantially, although sales of light-alcohol refreshers remained favorable. In addition, sales of seasonings also declined, while sales of raw alcohol and other products rose owing to their demand as disinfectant.

As a result, net sales for the Takara Shuzo Group increased 0.7% year on year to ¥119,757 million. Cost of sales was up 0.7% year on year to ¥72,111 million. Gross profit increased 0.7% year on year to ¥47,646 million. SG&A expenses were down 2% year on year to ¥41,501 million due to decreases in promotion expenses and other expenses, and operating income was up 23.3% year on year to ¥6,145 million.

[Takara Shuzo International Group]

In the nine months ended December 31, 2020, net sales were severely impacted as demand declined from major customers of both the Overseas Alcoholic Beverages Business and the Japanese Food Wholesale Business in overseas markets, primarily dining establishments, as a result of lockdowns that took place around the world. In the Overseas Alcoholic Beverages Business, sales of whiskey were robust while sales of sake declined. The Japanese Food Wholesale Business in overseas markets engaged in efforts to bolster sales to retailers and also to seize upon demand for home delivery and takeout. However, being unable to offset a decline in sales to major dining establishments, net sales declined.

As a result, net sales for the Takara Shuzo International Group decreased 17.7% year on year to ¥49,768 million. Cost of sales decreased 19.3% year on year to ¥34,877 million. Consequently, gross profit fell 13.8% year on year to ¥14,891 million. SG&A expenses were down 4.7% year on year to ¥14,253 million due to decreases in personnel expenses and other expenses, while operating income decreased 72.4% year on year to ¥637 million.

[Takara Bio Group]

In the nine months ended December 31, 2020, sales of research reagents and contract research services increased year on year, despite a year-on-year decrease in gene therapy sales. In addition, sales of polymerase chain reaction (PCR)-related products, including in-vitro diagnostics for COVID-19, launched in November 2020, grew.

As a result, net sales for the Takara Bio Group were up 20.3%year on year to ¥29,549 million. Cost of sales fell 15% year on year to ¥8,297 million due to change in sales composition and a higher production operation rate which drove the cost rate downward. Gross profit increased 43.7% year on year to ¥21,251 million. SG&A expenses were up 14.2% year on year to ¥12,460 million due to increases in research and development expenses and other expenses, and operating income was up 126.6% year on year to ¥8,791 million.

[Other]

In the nine months ended December 31, 2020, net sales of the Other segment declined 7.9% year on year to ¥22,689 million largely due to effects of the spread of COVID-19. Cost of sales declined 7.7% year on year to ¥19,744 million. Consequently,

gross profit decreased 9.4% year on year to ¥2,944 million. SG&A expenses fell 7.2% year on year to ¥1,423 million due to a decline in administrative expenses and other expenses, and operating income was down 11.4% year on year to ¥1,520 million.

Breakdown of sales results by product category

Segment	Equivalent Period of Previous Fiscal Year (From April 1, 2019, to December 31, 2019)	Period under Review (from April 1, 2020, to December 31, 2020)	YoY Comparison
Product category	Amount (Millions of yen)	Amount (Millions of yen)	(%)
Takara Shuzo			
Shochu	38,026	38,188	100.4
Sake	16,860	14,362	85.2
Light-alcohol refreshers	32,712	36,356	111.1
Other alcoholic beverages	4,861	4,330	89.1
Alcoholic beverages total	92,460	93,237	100.8
Hon Mirin	11,238	10,706	95.3
Other seasonings	8,222	8,232	100.1
Seasonings total	19,461	18,938	97.3
Raw alcohol, etc.	6,975	7,581	108.7
Total	118,897	119,757	100.7
Takara Shuzo International Group			
Overseas Alcoholic Beverages Business	8,010	7,279	90.9
Japanese Food Wholesales Business in overseas markets	53,881	43,344	80.4
Other	190	45	23.7
Elimination of intra-Group transaction on consolidation	(1,622)	(899)	—
Total	60,461	49,768	82.3
Takara Bio Group	24,558	29,549	120.3
Reported segment total	203,917	199,075	97.6
Other	24,644	22,689	92.1
Segment total	228,562	221,764	97.0
Sales not allocated to business segments and intersegment transactions	(16,389)	(14,826)	—
Total	212,172	206,938	97.5

Note: Amounts include alcohol tax but do not include consumption tax.

(2) Consolidated Financial Position

As of December 31, 2020, current assets were ¥185,998 million, an increase of ¥17,178 million compared with that at the end of the previous fiscal year. This was primarily due to an increase of ¥13,224 million in notes and accounts receivable-trade as well as an increase in cash and deposits of ¥11,122 million and a decline in securities of ¥6,346 million partly as a result of converting securities to cash in order to increase liquidity on hand.

Noncurrent assets were ¥120,727 million, an increase of ¥5,665 million compared with the end of the previous fiscal year. This was primarily due to an increase of ¥4,791 million in property, plant and equipment on account of acquiring land and a building as a new location for Takara Bio USA, Inc.

As a result, total assets were ¥306,726 million, an increase of ¥22,844 million compared with that at the end of the previous fiscal year.

As of December 31, 2020, current liabilities were ¥60,790 million, an increase of ¥5,323 million compared with that at the end of the previous fiscal year. This was primarily due to an increase of ¥4,785 million in other under current liabilities, an increase of ¥4,033 million in accrued alcohol tax owing to December 31, 2020 falling on a holiday, etc., and a decrease in current portion of bonds of ¥5,000 million.

Noncurrent liabilities were ¥57,876 million, an increase of ¥10,789 million compared with that at the end of the previous

fiscal year. This was primarily due to an increase in long-term loans payable of ¥10,045 million.

As a result, total liabilities were ¥118,666 million, an increase of ¥16,113 million compared with that at the end of the previous fiscal year.

As of December 31, 2020, total net assets were ¥188,059 million, an increase of ¥6,730 million compared with that at the end of the previous fiscal year. This was primarily due to an increase of ¥5,314 million in retained earnings.

As a result, the equity ratio totaled 50.0%, compared with 52.1% at the end of the previous fiscal year.

(3) Qualitative Information Regarding Consolidated Forecasts

The Company has revised the full-year consolidated results forecasts published on November 10, 2020 in view of the consolidated business results in the nine months ended December 31, 2020 and recent circumstances.

Overall consolidated net sales for the Takara Group are expected to exceed the previous forecast by ¥3,000 million (1.1%) as net sales for the Takara Bio Group and the Takara Shuzo International Group are projected to be larger than the forecast, although net sales for Takara Shuzo will be a little lower than the forecast.

In terms of profit, operating income, ordinary income, and net income attributable to owners of the parent are expected to exceed the previous forecast by ¥5,400 million (39.1%), ¥5,300 million (37.9%), and ¥2,600 million (36.6%), respectively, as a sales increase and a lower cost of sales rate raised gross profit and SG&A expenses were held down. Operating income and ordinary income are projected to be an all-time high.

For further details of the revision to the consolidated business results forecast, please refer to “Revision of Consolidated Business Results for the Fiscal Year Ending March 31, 2021,” announced today (February 10, 2021). Also, for the details of forecasts for each business segment, please refer to pages 8/13 to 11/13 in “Supplement for the Consolidated Financial Statements.”

(Full-Year Consolidated Results Forecasts for the fiscal year ending March 31, 2021)

	Net sales	Operating income	Ordinary income	Net income attributable to owners of the parent	Net income per share
Previous forecast (A) (Published November 10, 2020)	(Millions of yen) 274,000	(Millions of yen) 13,800	(Millions of yen) 14,000	(Millions of yen) 7,100	(Yen) 35.91
Revised forecast (B)	277,000	19,200	19,300	9,700	49.06
Difference (B – A)	3,000	5,400	5,300	2,600	―
Difference (%)	1.1	39.1	37.9	36.6	―
Reference: Business results for previous fiscal year (Ended March 31, 2020)	281,191	15,836	16,269	8,980	45.11

2. Consolidated Quarterly Financial Statements and Primary Notes

(1) Consolidated Balance Sheets

(Millions of Yen)

	As of Mar. 31, 2020	As of Dec. 31, 2020
Assets		
Current assets		
Cash and deposits	47,265	58,387
Notes and accounts receivable-trade	61,017	74,242
Securities	7,352	1,006
Merchandise and finished goods	42,295	39,977
Work in process	1,801	2,131
Raw materials and supplies	4,879	6,085
Other	4,515	4,705
Allowance for doubtful accounts	(307)	(538)
Total current assets	168,820	185,998
Noncurrent assets		
Property, plant and equipment	69,835	74,627
Intangible assets		
Goodwill	11,750	10,853
Other	6,950	5,860
Total intangible assets	18,700	16,713
Investments and other assets		
Investment securities	21,720	24,699
Other	4,873	4,755
Allowance for doubtful accounts	(69)	(69)
Total investments and other assets	26,525	29,386
Total noncurrent assets	115,061	120,727
Total assets	283,882	306,726

(Millions of Yen)

	As of Mar. 31, 2020	As of Dec. 31, 2020
Liabilities		
Current liabilities		
Notes and accounts payable-trade	16,440	16,770
Short-term loans payable	4,787	5,253
Current portion of bonds	5,000	—
Accrued alcohol tax	7,690	11,723
Accrued expenses	5,511	6,022
Income taxes payable	1,886	3,149
Provision	5,224	4,159
Other	8,926	13,711
Total current liabilities	55,466	60,790
Noncurrent liabilities		
Bonds payable	20,000	20,000
Long-term loans payable	5,448	15,493
Lease obligations	3,538	3,091
Net defined benefit liability	9,065	9,180
Long-term deposits received	5,363	5,199
Other	3,670	4,911
Total noncurrent liabilities	47,086	57,876
Total liabilities	102,553	118,666
Net assets		
Shareholders' equity		
Capital stock	13,226	13,226
Capital surplus	2,454	2,454
Retained earnings	128,564	133,878
Treasury stock	(1,682)	(1,682)
Total shareholders' equity	142,563	147,876
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	7,125	9,195
Deferred gains or losses on hedges	84	(36)
Foreign currency translation adjustment	(1,102)	(2,830)
Remeasurements of defined benefit plans	(908)	(901)
Total accumulated other comprehensive income	5,199	5,426
Noncontrolling interests	33,566	34,756
Total net assets	181,329	188,059
Total liabilities and net assets	283,882	306,726

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

(Consolidated Statements of Income)

(For the Nine Months Ended December 31, 2020 and 2019)

(Millions of Yen)

	FY2020 (Apr. 1, 2019 – Dec. 31, 2019)	FY2021 (Apr. 1, 2020 – Dec. 31, 2020)
Net sales	212,172	206,938
Cost of sales	130,168	120,738
Gross profit	82,004	86,199
Selling, general and administrative expenses	69,167	69,012
Operating income	12,836	17,186
Non-operating income		
Dividends income	585	513
Other	697	497
Total non-operating income	1,283	1,011
Non-operating expenses		
Interest expenses	303	263
Other	525	366
Total non-operating expenses	829	630
Ordinary income	13,290	17,568
Extraordinary income		
Gain on sales of investment securities	1,130	—
National subsidies	—	35
Other	163	8
Total extraordinary income	1,294	43
Extraordinary loss		
Loss on sales and retirement of non-current assets	233	183
Loss on business liquidation	—	462
Provision for environmental measures	415	—
Other	139	152
Total extraordinary losses	787	798
Income before income taxes	13,797	16,813
Income taxes-current	4,019	5,074
Income taxes-deferred	305	347
Total income taxes	4,324	5,422
Net income	9,473	11,390
Net income attributable to the noncontrolling interest	1,172	2,122
Net income attributable to owners of the parent	8,300	9,268

(Consolidated Statements of Comprehensive Income)

(For the Nine Months Ended December 31, 2020 and 2019)

(Millions of Yen)

	FY2020 (Apr. 1, 2019 – Dec. 31, 2019)	FY2021 (Apr. 1, 2020 – Dec. 31, 2020)
Net income	9,473	11,390
Other comprehensive income		
Valuation difference on available-for-sale securities	785	2,070
Deferred gains or losses on hedges	(13)	(121)
Foreign currency translation adjustment	(3,820)	(2,275)
Remeasurements of defined benefit plans	(18)	18
Total other comprehensive income	(3,067)	(307)
Comprehensive income	6,406	11,083
(Comprehensive income attributable to)		
Comprehensive income attributable to owners of the parent	5,969	9,495
Comprehensive income attributable to noncontrolling interest	436	1,587

(3) Notes on Consolidated Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes on Material Changes in Shareholders' Equity)

No items to report.

(Segment Information)

I. Equivalent Period of Previous Fiscal Year (From April 1, 2019 to December 31, 2019)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	118,411	60,214	24,557	203,183	8,984	212,167	5	212,172
Intersegment	485	246	1	733	15,660	16,394	(16,394)	
Total	118,897	60,461	24,558	203,917	24,644	228,562	(16,389)	212,172
Segment income	4,983	2,313	3,879	11,176	1,716	12,892	(56)	12,836

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business and the transportation business of domestic Group companies among others.

2. Details of adjustment amounts are as follows.

(1) Net sales to external customers are income from business contracting recorded at the Company.

(2) Segment income comprises intersegment eliminations of ¥36 million and loss of the Company not allocated to business segments of ¥92 million.

3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

No items to report.

II. Period under Review (From April 1, 2020, to December 31, 2020)

1. Net sales and Income (Loss) by Reported Segment

(Millions of yen)

	Reported Segment				Other (Note: 1)	Total	Adjustment (Note: 2)	Amount recognized in consolidated quarterly statements of income (Note: 3)
	Takara Shuzo	Takara Shuzo International Group	Takara Bio Group	Subtotal				
Net sales								
External customers	119,349	49,589	29,548	198,487	8,450	206,938	0	206,938
Intersegment	408	179	0	587	14,239	14,826	(14,826)	-
Total	119,757	49,768	29,549	199,075	22,689	221,764	(14,826)	206,938
Segment income	6,145	637	8,791	15,574	1,520	17,094	91	17,186

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business and the transportation business of domestic Group companies among others.

2. Details of adjustment amounts are as follows.
   (1) Net sales to external customers are income from business contracting recorded at the Company.
   (2) Segment income comprises intersegment eliminations of ¥43 million and income of the Company not allocated to business segments of ¥48 million.
3. Segment income has been adjusted to the operating income of consolidated quarterly statements of income.

2. Information on Impairment Loss on Noncurrent Assets, Goodwill, etc. by Reportable Segment

The Company posted a ¥363 million impairment loss in line with the liquidation of the next-generation sequencing library manufacturing equipment-related business, in the “Takara Bio Group” segment. This impairment loss is posted as “loss on business liquidation” under extraordinary loss, together with related loss.

2021年3月期
第3四半期決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Third Quarter Ended December 31, 2020

1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書
Consolidated Statements of Income by Business Group (Summary)

2. 宝酒造
Takara Shuzo

要約損益計算書
Statements of Income (Summary)

3. 宝酒造インターナショナルグループ
Takara Shuzo International Group

要約損益計算書
Statements of Income (Summary)

4. タカラバイオグループ
Takara Bio Group

要約損益計算書
Statements of Income (Summary)

5. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group

6. 2021年3月期第3四半期　参考資料
Reference Data for the Third Quarter Ended December 31, 2020

7. 2021年3月期　連結業績予想
Financial forecast for the year ending March 31, 2021

① 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-

② 宝酒造
Takara Shuzo

③ 宝酒造インターナショナルグループ
Takara Shuzo International Group

④ タカラバイオグループ
Takara Bio Group

8. 2021年3月期　参考資料
Reference Data for the year ending March 31, 2021

宝ホールディングス株式会社
TAKARA HOLDINGS INC.

財務・IR部 Financial & Investor Relations Dept.

TEL 075(241)5124
FAX 075(241)5127
E-Mail ir@takara.co.jp

将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

Forward-Looking Statements

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　財務・IR部
Takara Holdings Inc.　Financial & Investor Relations Dept.
TEL 075(241)5124　FAX 075(241)5127
E-Mail ir@takara.co.jp

1. 宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-

グループ別要約損益計算書 Consolidated Statements of Income by Business Group (Summary)

(百万円 Millions of Yen)

	2020年3月期 第3四半期累計	2021年3月期 第3四半期累計 Apr. 1, 2020 - Dec. 31, 2020		
	実績(a) FY2020(1Q-3Q) Actual (a)	実績(b) FY2021(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
宝酒造 Takara Shuzo	118,897	119,757	860	100.7%
宝酒造インターナショナルグループ Takara Shuzo International Group	60,461	49,768	△ 10,692	82.3%
タカラバイオ グループ Takara Bio Group	24,558	29,549	4,990	120.3%
その他 Other	24,644	22,689	△ 1,955	92.1%
調整額 Adjustment	△ 16,389	△ 14,826	1,562	―
売上高 Net sales	212,172	206,938	△ 5,234	97.5%
売上原価 Cost of sales	130,168	120,738	△ 9,429	92.8%
売上総利益 Gross profit	82,004	86,199	4,195	105.1%
運送費、保管料 Transportation and storage	8,334	8,338	4	100.0%
広告宣伝費 Advertising	1,645	1,591	△ 54	96.7%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	26,071	25,368	△ 703	97.3%
研究開発費 Research and development	3,112	3,928	815	126.2%
管理費、その他 Other, net	30,002	29,786	△ 216	99.3%
販売費及び一般管理費 SG&A expenses	69,167	69,012	△ 154	99.8%
宝酒造 Takara Shuzo	4,983	6,145	1,161	123.3%
宝酒造インターナショナルグループ Takara Shuzo International Group	2,313	637	△ 1,675	27.6%
タカラバイオ グループ Takara Bio Group	3,879	8,791	4,911	226.6%
その他 Other	1,716	1,520	△ 195	88.6%
調整額 Adjustment	△ 56	91	147	―
営業利益(△:損失) Operating income(Δ:loss)	12,836	17,186	4,349	133.9%
受取利息・配当金 Interest and Dividends income	788	629	△ 158	79.9%
その他営業外収益 Other, net	495	382	△ 112	77.2%
営業外収益 Non-operating income	1,283	1,011	△ 271	78.8%
支払利息 Interest and discounts expenses	303	263	△ 40	86.7%
その他営業外費用 Other, net	525	366	△ 159	69.7%
営業外費用 Non-operating expenses	829	630	△ 199	76.0%
経常利益(△:損失) Ordinary income(Δ:loss)	13,290	17,568	4,277	132.2%
特別利益 Extraordinary income	1,294	43	△ 1,251	3.4%
特別損失 Extraordinary loss	787	798	10	101.3%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	13,797	16,813	3,015	121.9%
法人税、住民税及び事業税 Current income taxes	4,019	5,074	1,055	126.3%
法人税等調整額 Deferred income taxes	305	347	42	114.0%
四半期純利益(△:損失) Net income(Δ:loss)	9,473	11,390	1,917	120.2%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	1,172	2,122	950	181.1%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	8,300	9,268	967	111.7%
設備投資額(有形・無形) Capital expenditures	10,635	11,010	375	103.5%
減価償却費(有形・無形) Depreciation and Amortization	5,310	6,005	694	113.1%
のれん償却額 Amortization of goodwill	629	649	20	103.3%

営業外収益 Non-operating income	受取配当金 513 など Dividend income 513, etc.
営業外費用 Non-operating expenses	支払利息 263 など Interest expense 263, etc.
特別利益 Extraordinary income	(前期:投資有価証券売却益 1,130など) (FY2020: Gain on sales of investment securities 1,130 etc)
特別損失 Extraordinary loss	事業整理損 462 など Loss on liquidation of business 462, etc.

2. 宝酒造 :Takara Shuzo

要約損益計算書 Statements of Income (Summary)

	2020年3月期 第3四半期累計	2021年3月期 第3四半期累計 Apr. 1, 2020 - Dec. 31, 2020		
	実績(a) FY2020(1Q-3Q) Actual (a)	実績(b) FY2021(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
焼酎 Shochu	38,026	38,188	161	100.4%
清酒 Sake	16,860	14,362	△ 2,497	85.2%
ソフトアルコール飲料 Light-alcohol refreshers	32,712	36,356	3,644	111.1%
その他酒類 Other liquors	4,861	4,330	△ 531	89.1%
本みりん Hon Mirin	11,238	10,706	△ 532	95.3%
その他調味料 Other seasonings	8,222	8,232	9	100.1%
原料用アルコール等 Raw alcohol	6,975	7,581	606	108.7%
売上高 Net sales	118,897	119,757	860	100.7%
売上原価 Cost of sales	71,578	72,111	532	100.7%
売上総利益 Gross profit	47,318	47,646	328	100.7%
運送費、保管料 Transportation and storage	6,286	6,364	78	101.2%
広告宣伝費 Advertising	1,524	1,497	△ 27	98.2%
販売促進費 Sales promotion	25,184	24,582	△ 601	97.6%
研究開発費 Research and development	295	267	△ 28	90.5%
管理費、その他 Other, net	9,044	8,788	△ 255	97.2%
販売費及び一般管理費 SG&A expenses	42,334	41,501	△ 833	98.0%
営業利益(△:損失) Operating income(Δ:loss)	4,983	6,145	1,161	123.3%
営業外収益 Non-operating income	288	193	△ 95	67.1%
営業外費用 Non-operating expenses	274	223	△ 51	81.3%
経常利益(△:損失) Ordinary income(Δ:loss)	4,998	6,115	1,117	122.4%
特別利益 Extraordinary income	124	0	△ 123	0.1%
特別損失 Extraordinary loss	260	159	△ 100	61.2%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	4,861	5,956	1,094	122.5%
法人税、住民税及び事業税 Current income taxes	1,431	1,798	367	125.6%
法人税等調整額 Deferred income taxes	141	42	△ 98	30.4%
四半期純利益(△:損失) Net income(Δ:loss)	3,288	4,115	826	125.1%
設備投資額(有形・無形) Capital expenditures	4,616	723	△ 3,893	15.7%
減価償却費(有形・無形) Depreciation and Amortization	1,934	2,114	180	109.3%

(注)2020年3月期の実績において、「ソフトアルコール飲料」「その他酒類」の売上高の一部を前回発表時から組み替えております。

3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

要約損益計算書 Statements of Income (Summary)

	2020年3月期 第3四半期累計	2021年3月期 第3四半期累計 Apr. 1, 2020 - Dec. 31, 2020		
	実績(a) FY2020(1Q-3Q) Actual (a)	実績(b) FY2021(1Q-3Q) Actual (b)	増減(b−a) Change (b-a)	比(b/a) YOY% (b/a)
海外酒類事業 Overseas Alcoholic beverages business	8,010	7,279	△ 731	90.9%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	53,881	43,344	△ 10,537	80.4%
その他 Other	190	45	△ 145	23.7%
連結消去 Elimination	△ 1,622	△ 899	722	−
売上高 Net sales	60,461	49,768	△ 10,692	82.3%
売上原価 Cost of sales	43,194	34,877	△ 8,317	80.7%
売上総利益 Gross profit	17,266	14,891	△ 2,375	86.2%
運送費、保管料 Transportation and storage	1,965	1,647	△ 317	83.8%
広告宣伝費 Advertising	63	47	△ 16	73.8%
販売促進費 Sales promotion	537	358	△ 179	66.6%
管理費、その他 Other, net	12,387	12,201	△ 185	98.5%
販売費及び一般管理費 SG&A expenses	14,953	14,253	△ 699	95.3%
海外酒類事業 Overseas Alcoholic beverages business	1,534	1,543	8	100.6%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	1,962	219	△ 1,743	11.2%
その他 Other	△ 627	△ 795	△ 168	−
連結消去 Elimination	△ 556	△ 330	226	−
営業利益(△:損失) Operating income(Δ:loss)	2,313	637	△ 1,675	27.6%
営業外収益 Non-operating income	245	94	△ 151	38.3%
営業外費用 Non-operating expenses	251	197	△ 54	78.5%
経常利益(△:損失) Ordinary income(Δ:loss)	2,307	534	△ 1,773	23.2%
特別利益 Extraordinary income	39	2	△ 37	5.9%
特別損失 Extraordinary loss	13	36	23	270.2%
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	2,333	499	△ 1,833	21.4%
法人税、住民税及び事業税 Current income taxes	708	148	△ 560	20.9%
法人税等調整額 Deferred income taxes	24	28	4	120.3%
四半期純利益(△:損失) Net income(Δ:loss)	1,600	322	△ 1,277	20.2%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	104	△ 138	△ 242	−
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	1,496	461	△ 1,034	30.8%
設備投資額(有形・無形) Capital expenditures	1,436	2,324	888	161.9%
減価償却費(有形・無形) Depreciation and Amortization	874	1,049	174	120.0%
のれん償却額 Amortization of goodwill	256	282	25	110.1%

4. タカラバイオグループ :Takara Bio Group

要約損益計算書 Statements of Income (Summary)

	2020年3月期 第3四半期累計	2021年3月期 第3四半期累計 Apr. 1, 2020 - Dec. 31, 2020		
	実績(a) FY2020(1Q-3Q) Actual (a)	実績(b) FY2021(1Q-3Q) Actual (b)	増減(b-a) Change (b-a)	比(b/a) YOY% (b/a)
研究用試薬 Research reagents	18,042	22,615	4,573	125.3%
理化学機器 Scientific instruments	952	1,113	161	116.9%
受託サービス Contracted service	3,392	5,575	2,183	164.3%
遺伝子医療 Gene Therapy	2,170	243	△ 1,927	11.2%
売上高 Net sales	24,558	29,549	4,990	120.3%
売上原価 Cost of sales	9,767	8,297	△ 1,469	85.0%
売上総利益 Gross profit	14,791	21,251	6,460	143.7%
運送費、保管料 Transportation and storage	332	545	212	163.9%
広告宣伝費 Advertising	52	40	△ 11	77.4%
販売促進費 Sales promotion	434	489	54	112.7%
研究開発費 Research and development	2,812	3,656	843	130.0%
管理費、その他 Other, net	7,279	7,728	448	106.2%
販売費及び一般管理費 SG&A expenses	10,911	12,460	1,548	114.2%
営業利益(△:損失) Operating income(Δ:loss)	3,879	8,791	4,911	226.6%
営業外収益 Non-operating income	212	205	△ 6	96.7%
営業外費用 Non-operating expenses	195	77	△ 118	39.5%
経常利益(△:損失) Ordinary income(Δ:loss)	3,896	8,919	5,023	228.9%
特別利益 Extraordinary income	0	36	35	―
特別損失 Extraordinary loss	13	596	582	―
税金等調整前四半期純利益(△:損失) Income(Δ:loss) before income taxes	3,883	8,359	4,476	215.3%
法人税、住民税及び事業税 Current income taxes	935	2,693	1,758	287.9%
法人税等調整額 Deferred income taxes	229	△ 83	△ 313	―
四半期純利益(△:損失) Net income(Δ:loss)	2,717	5,749	3,031	211.6%
非支配株主に帰属する四半期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	8	22	13	257.3%
親会社株主に帰属する四半期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	2,708	5,726	3,018	211.4%
設備投資額(有形・無形) Capital expenditures	4,167	7,469	3,302	179.2%
減価償却費(有形・無形) Depreciation and Amortization	2,102	2,421	318	115.1%
のれん償却額 Amortization of goodwill	372	367	△ 5	98.6%

(注)2021年3月期より、報告セグメントを単一セグメントに変更したため、2020年3月期の実績を組み替えて表示しております。
(注)「研究用試薬」の売上高には、当第3四半期連結会計期間に発売した対外診断用医薬品の売上高を含めております。

5. 6年間の財務サマリー(グループ別) :Six-Year Financial Summary by Business Group

宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

		2016年3月期 第3四半期 FY2016(1Q-3Q)	2017年3月期 第3四半期 FY2017(1Q-3Q)	2018年3月期 第3四半期 FY2018(1Q-3Q)	2019年3月期 第3四半期 FY2019(1Q-3Q)	2020年3月期 第3四半期 FY2020(1Q-3Q)	2021年3月期 第3四半期 FY2021(1Q-3Q)	前期対比 Change from FY2020(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	170,250	172,218	204,266	210,622	212,172	206,938	△ 5,234	97.5%
売上原価	Cost of sales	102,349	101,336	124,486	127,706	130,168	120,738	△ 9,429	92.8%
(売上高原価率)	(Ratio to Net sales)	60.1%	58.8%	60.9%	60.6%	61.4%	58.3%	-3.0pt	–
売上総利益	Gross profit	67,901	70,881	79,779	82,915	82,004	86,199	4,195	105.1%
販売費及び一般管理費	SG&A expenses	57,809	58,139	66,175	67,900	69,167	69,012	△ 154	99.8%
(売上高販管費率)	(Ratio to Net sales)	34.0%	33.8%	32.4%	32.2%	32.6%	33.3%	+0.8pt	–
営業利益(△:損失)	Operating income(Δ:loss)	10,091	12,741	13,604	15,015	12,836	17,186	4,349	133.9%
(売上高営業利益率)	(Ratio to Net Sales)	5.9%	7.4%	6.7%	7.1%	6.1%	8.3%	+2.3pt	–
販売促進費	Sales promotion	24,561	25,020	24,840	25,131	26,071	25,368	△ 703	97.3%
(売上高販促費率)	(Ratio to Net sales)	14.4%	14.5%	12.2%	11.9%	12.3%	12.3%	-0.0pt	–
研究開発費	R&D expenses	3,363	3,155	3,726	3,444	3,112	3,928	815	126.2%
(売上高研究開発費率)	(Ratio to Net sales)	2.0%	1.8%	1.8%	1.6%	1.5%	1.9%	+0.4pt	–
設備投資額(有形・無形)	Capital expenditures	3,768	3,749	3,738	5,156	10,635	11,010	375	103.5%
減価償却費(有形・無形)	Depreciation and Amortization	3,820	3,753	4,767	4,813	5,310	6,005	694	113.1%
のれん償却額	Amortization of goodwill	404	349	625	646	629	649	20	103.3%

宝酒造 :Takara Shuzo

(百万円 :Millions of Yen)

		2016年3月期 第3四半期 FY2016(1Q-3Q)	2017年3月期 第3四半期 FY2017(1Q-3Q)	2018年3月期 第3四半期 FY2018(1Q-3Q)	2019年3月期 第3四半期 FY2019(1Q-3Q)	2020年3月期 第3四半期 FY2020(1Q-3Q)	2021年3月期 第3四半期 FY2021(1Q-3Q)	前期対比 Change from FY2020(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	–	116,025	117,845	119,001	118,897	119,757	860	100.7%
売上原価	Cost of sales	–	68,731	70,038	70,919	71,578	72,111	532	100.7%
(売上高原価率)	(Ratio to Net sales)		59.2%	59.4%	59.6%	60.2%	60.2%	+0.0pt	–
売上総利益	Gross profit		47,293	47,806	48,081	47,318	47,646	328	100.7%
販売費及び一般管理費	SG&A expenses		41,112	41,108	41,397	42,334	41,501	△ 833	98.0%
(売上高販管費率)	(Ratio to Net sales)		35.4%	34.9%	34.8%	35.6%	34.7%	-1.0pt	–
営業利益(△:損失)	Operating income(Δ:loss)		6,181	6,698	6,683	4,983	6,145	1,161	123.3%
(売上高営業利益率)	(Ratio to Net sales)		5.3%	5.7%	5.6%	4.2%	5.1%	+0.9pt	–
販売促進費	Sales promotion		24,054	23,864	24,148	25,184	24,582	△ 601	97.6%
(売上高販促費率)	(Ratio to Net sales)		20.7%	20.3%	20.3%	21.2%	20.5%	-0.7pt	–
設備投資額(有形・無形)	Capital expenditures	–	1,094	1,348	1,019	4,616	723	△ 3,893	15.7%
減価償却費(有形・無形)	Depreciation and Amortization	–	1,607	1,626	1,647	1,934	2,114	180	109.3%

2018年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

宝酒造インターナショナルグループ :Takara Shuzo International Group

(百万円 :Millions of Yen)

		2016年3月期 第3四半期 FY2016(1Q-3Q)	2017年3月期 第3四半期 FY2017(1Q-3Q)	2018年3月期 第3四半期 FY2018(1Q-3Q)	2019年3月期 第3四半期 FY2019(1Q-3Q)	2020年3月期 第3四半期 FY2020(1Q-3Q)	2021年3月期 第3四半期 FY2021(1Q-3Q)	前期対比 Change from FY2020(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	–	22,021	51,364	56,843	60,461	49,768	△ 10,692	82.3%
売上原価	Cost of sales	–	14,801	36,170	40,196	43,194	34,877	△ 8,317	80.7%
(売上高原価率)	(Ratio to Net sales)		67.2%	70.4%	70.7%	71.4%	70.1%	-1.4pt	–
売上総利益	Gross profit		7,220	15,194	16,647	17,266	14,891	△ 2,375	86.2%
販売費及び一般管理費	SG&A expenses		5,264	11,988	13,416	14,953	14,253	△ 699	95.3%
(売上高販管費率)	(Ratio to Net sales)		23.9%	23.3%	23.6%	24.7%	28.6%	+3.9pt	–
営業利益(△:損失)	Operating income(Δ:loss)		1,955	3,206	3,230	2,313	637	△ 1,675	27.6%
(売上高営業利益率)	(Ratio to Net sales)		8.9%	6.2%	5.7%	3.8%	1.3%	-2.5pt	–
設備投資額(有形・無形)	Capital expenditures		404	1,130	832	1,436	2,324	888	161.9%
減価償却費(有形・無形)	Depreciation and Amortization	–	417	698	748	874	1,049	174	120.0%
のれん償却額	Amortization of goodwill	–	227	261	272	256	282	25	110.1%

2018年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

タカラバイオグループ :Takara Bio Group

(百万円 :Millions of Yen)

		2016年3月期 第3四半期 FY2016(1Q-3Q)	2017年3月期 第3四半期 FY2017(1Q-3Q)	2018年3月期 第3四半期 FY2018(1Q-3Q)	2019年3月期 第3四半期 FY2019(1Q-3Q)	2020年3月期 第3四半期 FY2020(1Q-3Q)	2021年3月期 第3四半期 FY2021(1Q-3Q)	前期対比 Change from FY2020(1Q-3Q) 増減 Change	比 YOY%
売上高	Net sales	20,706	20,645	22,646	25,888	24,558	29,549	4,990	120.3%
売上原価	Cost of sales	9,199	8,106	9,879	10,947	9,767	8,297	△ 1,469	85.0%
(売上高原価率)	(Ratio to Net sales)	44.4%	39.3%	43.6%	42.3%	39.8%	28.1%	-11.7pt	–
売上総利益	Gross profit	11,507	12,538	12,766	14,940	14,791	21,251	6,460	143.7%
販売費及び一般管理費	SG&A expenses	10,062	9,813	11,157	11,507	10,911	12,460	1,548	114.2%
(売上高販管費率)	(Ratio to Net sales)	48.6%	47.5%	49.3%	44.5%	44.4%	42.2%	-2.3pt	–
営業利益(△:損失)	Operating income(Δ:loss)	1,444	2,724	1,608	3,432	3,879	8,791	4,911	226.6%
(売上高営業利益率)	(Ratio to Net sales)	7.0%	13.2%	7.1%	13.3%	15.8%	29.8%	+14.0pt	–
研究開発費	R&D expenses	3,118	2,870	3,417	3,164	2,812	3,656	843	130.0%
(売上高研究開発費率)	(Ratio to Net sales)	15.1%	13.9%	15.1%	12.2%	11.5%	12.4%	+0.9pt	–
設備投資額(有形・無形)	Capital expenditures	1,850	1,200	910	3,124	4,167	7,469	3,302	179.2%
減価償却費(有形・無形)	Depreciation and Amortization	1,247	1,276	1,896	2,014	2,102	2,421	318	115.1%
のれん償却額	Amortization of goodwill	135	121	364	374	372	367	△ 5	98.6%

6. 2021年3月期第3四半期 参考資料 :Reference Data for the Third Quarter Ended December 31, 2020

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	2020年3月期 第3四半期累計	2021年3月期 第3四半期累計 Apr. 1, 2020 - Dec. 31, 2020	
	実績(a) FY2020(1Q-3Q) Actual (a)	実績(b) FY2021(1Q-3Q) Actual (b)	前期差 Change(c-a)
米ドル : US dollar	109.13	107.57	△ 1.56
ポンド: Pound	138.95	136.69	△ 2.26
ユーロ: Euro	122.62	120.94	△ 1.68
人民元: Yuan	15.89	15.37	△ 0.52
100ウォン: 100 Won	9.40	8.96	△ 0.44
インドルピー: Rupee	1.56	1.45	△ 0.11
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	11.61	11.46	△ 0.15
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	79.99	77.36	△ 2.63
ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar	76.31	72.77	△ 3.54

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2020(1Q-3Q)
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	△ 1,215
うち宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Net sales of Takara Shuzo International Group	△ 810
海外酒類事業 Overseas Alcoholic beverages business	△ 112
海外日本食材卸事業 Japanese food wholesale business in overseas markets	△ 708
その他 Other	―
連結消去 Elimination	11
うちタカラバイオグループ Net sales of Takara Bio Group	△ 407
研究用試薬 Research reagents	△ 367
理化学機器 Scientific instruments	△ 6
受託サービス Contracted service	△ 33
遺伝子医療 Gene Therapy	―

② 海外売上高比率 :Overseas sales ratio

(百万円 :Millions of Yen)

	2020年3月期第3四半期 実績 FY2020(1Q-3Q) Actual			2021年3月期第3四半期 実績 FY2021(1Q-3Q) Actual		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	118,897	―	―	119,757	―	―
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group	60,461	60,137	99.5%	49,768	49,555	99.6%
タカラバイオグループ Takara Bio Group	24,558	14,665	59.7%	29,549	17,123	58.0%
その他および調整額 Other / Adjustment	8,255	―	―	7,862	―	―
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	212,172	74,803	35.3%	206,938	66,679	32.2%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2020年3月期第3四半期 実績 FY2020(1Q-3Q) Actual		2021年3月期第3四半期 実績 FY2021(1Q-3Q) Actual	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	25,930	2,433	19,401	△ 109
Takara Sake USA Inc.	百 万 円 :Millions of Yen	2,829	265	2,086	△ 11
宝酒造食品	千 元 :Thousands of Yuan	38,200	2,055	28,129	△ 32
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	607	32	432	△ 0
トマーチン	千 ポ ン ド :Thousands of Pound	13,739	3,381	14,079	4,349
The Tomatin Distillery Co.,Ltd.	百 万 円 :Millions of Yen	1,909	469	1,924	594
ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ドル :Thousands of US dollar	18,508	8,278	21,549	9,927
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	2,019	903	2,318	1,067
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	132,115	12,195	115,300	8,001
FOODEX Group	百 万 円 :Millions of Yen	16,200	1,495	13,944	967
タザキフーズ	千 ポ ン ド :Thousands of Pound	33,754	1,165	29,850	890
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	4,690	161	4,080	121
ミューチャルトレーディング	千 US ドル :Thousands of US dollar	273,307	4,194	203,223	△ 10,368
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	29,826	457	21,860	△ 1,115
ニッポンフード	千 AUS ドル :Thousands of Australian dollar	41,480	△ 1,992	36,808	1,382
Nippon Food Supplies Company Pty Ltd	百 万 円 :Millions of Yen	3,165	△ 152	2,678	100
東京共同貿易 Tokyo Mutual Trading Co., Ltd.	百 万 円 :Millions of Yen	―	―	4,637	159
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S. (連結)	千 ユ ー ロ :Thousands of Euro	18,790	600	29,703	4,327
Takara Bio Europe S.A.S. Consolidated	百 万 円 :Millions of Yen	2,304	73	3,592	523
宝生物工程(大連)	千 元 :Thousands of Yuan	154,543	45,445	267,153	137,600
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	2,455	722	4,106	2,114
宝日医生物技術(北京)	千 元 :Thousands of Yuan	291,921	57,363	357,386	71,185
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	4,638	911	5,493	1,094
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	8,100	1,254	9,332	1,563
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	761	117	836	140
タカラバイオDSSインド	千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	173,217	14,468	292,413	41,524
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	270	22	423	60
タカラバイオUSA	千 US ドル :Thousands of US dollar	73,491	8,242	73,497	3,281
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	8,020	899	7,906	353

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

(百万円 :Millions of Yen)

	対前期増減 Change from FY2020(1Q-3Q)		
	増減計 Total Change	数量差 Change in quantities	単価差 Change in unit price
売上総利益 計 Gross profit	+328	+911	△ 583
(主な内訳)			
焼酎 Shochu	+188	+42	+146
清酒 Sake	△ 1,103	△ 1,043	△ 59
ｿﾌﾄｱﾙｺｰﾙ飲料 Light-alcohol refreshers	+1,445	+2,429	△ 984
本みりん Hon Mirin	△ 396	△ 290	△ 105
(参考)原価コストダウン Reference :Cost reduction	+253	※上記数量差および単価差に含む *Included in changes above	

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown「+」and「△」, respectively

⑤ 宝ホールディングス(連結)要約損益計算書(p.1)における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.1)

	2020年3月期第3四半期 実績 FY2020(1Q-3Q) Actual		2021年3月期第3四半期 実績 FY2021(1Q-3Q) Actual	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	11,043	523	10,613	478
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	400	336	380	315
その他 Other	13,200	856	11,695	727
「その他」計 Total "Other"	24,644	1,716	22,689	1,520

7. 2021年3月期 業績予想 :Financial forecast for the year ending March 31, 2021

① 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

	2020年3月期 FY2020	2021年3月期 FY2020_Apr. 1, 2020 - Mar. 31, 2021		対前期 Change from FY2020		対11/10予想 Change from forecast announced Nov. 2020	
	実績(a) Actual (a)	11/10予想(b) Forecast announced Nov. 2020 (b)	2/10予想(c) Forecast announced Feb. 2021 (c)	増減(c-a) Change (c-a)	比(c/a) % (c/a)	増減(c-b) Change (c-b)	比(c/b) % (c/b)
宝酒造 Takara Shuzo	153,141	154,502	152,788	△ 353	99.8%	△ 1,714	98.9%
宝酒造インターナショナルグループ Takara Shuzo International Group	82,765	68,374	69,273	△ 13,492	83.7%	899	101.3%
タカラバイオ グループ Takara Bio Group	34,565	40,800	45,200	10,634	130.8%	4,400	110.8%
その他 Other	31,801	29,392	29,234	△ 2,567	91.9%	△ 158	99.5%
調整額 Adjustment	△ 21,082	△ 19,068	△ 19,495	1,587	—	△ 427	—
売上高 Net sales	281,191	274,000	277,000	△ 4,191	98.5%	3,000	101.1%
売上原価 Cost of sales	172,574	164,700	163,500	△ 9,074	94.7%	△ 1,200	99.3%
売上総利益 Gross profit	108,617	109,300	113,500	4,882	104.5%	4,200	103.8%
運送費、保管料 Transportation and storage	11,000	11,100	10,900	△ 100	99.1%	△ 200	98.2%
広告宣伝費 Advertising	2,051	2,100	2,200	148	107.2%	100	104.8%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	35,073	35,000	34,500	△ 573	98.4%	△ 500	98.6%
研究開発費 Research and development	4,259	5,600	5,700	1,440	133.8%	100	101.8%
管理費、その他 Other, net	40,395	41,700	41,000	604	101.5%	△ 700	98.3%
販売費及び一般管理費 SG&A expenses	92,781	95,500	94,300	1,518	101.6%	△ 1,200	98.7%
宝酒造 Takara Shuzo	4,175	4,700	4,700	524	112.6%	—	100.0%
宝酒造インターナショナルグループ Takara Shuzo International Group	3,532	252	932	△ 2,600	26.4%	680	369.8%
タカラバイオ グループ Takara Bio Group	6,274	8,000	12,000	5,725	191.2%	4,000	150.0%
その他 Other	2,018	1,654	1,756	△ 262	87.0%	102	106.2%
調整額 Adjustment	△ 164	△ 806	△ 187	△ 23	—	618	—
営業利益(△:損失) Operating income(Δ:loss)	15,836	13,800	19,200	3,363	121.2%	5,400	139.1%
受取利息・配当金 Interest and Dividends income	911	700	700	△ 211	76.8%	—	100.0%
その他営業外収益 Other, net	547	400	500	△ 47	91.4%	100	125.0%
営業外収益 Non-operating income	1,458	1,100	1,200	△ 258	82.3%	100	109.1%
支払利息 Interest and discounts expenses	403	300	300	△ 103	74.3%	—	100.0%
その他営業外費用 Other, net	621	600	800	178	128.7%	200	133.3%
営業外費用 Non-operating expenses	1,025	900	1,100	74	107.3%	200	122.2%
経常利益(△:損失) Ordinary income(Δ:loss)	16,269	14,000	19,300	3,030	118.6%	5,300	137.9%
特別利益 Extraordinary income	1,473	10	90	△ 1,383	6.1%	80	900.0%
特別損失 Extraordinary loss	2,099	810	990	△ 1,109	47.2%	180	122.2%
税金等調整前当期純利益(△:損失) Income before income taxes(Δ:loss)	15,643	13,200	18,400	2,756	117.6%	5,200	139.4%
法人税、住民税及び事業税 Current income taxes	5,077	4,300	5,800	847	117.1%	1,500	134.9%
法人税等調整額 Deferred income taxes	△ 125						
当期純利益(△:損失) Net income(Δ:loss)	10,691	8,900	12,600	1,908	117.9%	3,700	141.6%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	1,710	1,800	2,900	1,189	169.5%	1,100	161.1%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	8,980	7,100	9,700	719	108.0%	2,600	136.6%
設備投資額(有形・無形) Capital expenditures	14,195	14,020	14,020	△ 175	98.8%	—	100.0%
減価償却費(有形・無形) Depreciation and Amortization	7,626	7,900	8,000	373	104.9%	100	101.3%
のれん償却額 Amortization of goodwill	847	860	860	12	101.5%	—	100.0%

② 宝酒造 :Takara Shuzo

（百万円 :Millions of Yen）

	2020年3月期 FY2020	2021年3月期 FY2020_Apr. 1, 2020 - Mar. 31, 2021		対前期 Change from FY2020		対11/10予想 Change from forecast announced Nov. 2020	
	実績(a) Actual (a)	11/10予想(b) Forecast announced Nov. 2020 (b)	2/10予想(c) Forecast announced Feb. 2021 (c)	増減(c-a) Change (c-a)	比(c/a) % (c/a)	増減(c-b) Change (c-b)	比(c/b) % (c/b)
焼酎 Shochu	49,728	49,269	49,104	△ 624	98.7%	△ 165	99.7%
清酒 Sake	20,488	17,172	17,757	△ 2,731	86.7%	585	103.4%
ソフトアルコール飲料 Light-alcohol refreshers	43,023	47,800	46,883	3,859	109.0%	△ 917	98.1%
その他酒類 Other liquors	6,405	5,747	5,640	△ 765	88.0%	△ 107	98.1%
本みりん Hon Mirin	13,980	13,994	13,244	△ 736	94.7%	△ 750	94.6%
その他調味料 Other seasonings	10,330	10,737	10,439	108	101.0%	△ 298	97.2%
原料用アルコール等 Raw alcohol	9,183	9,783	9,721	537	105.9%	△ 62	99.4%
売上高 Net sales	153,141	154,502	152,788	△ 353	99.8%	△ 1,714	98.9%
売上原価 Cost of sales	92,822	93,465	92,510	△ 312	99.7%	△ 955	99.0%
売上総利益 Gross profit	60,318	61,037	60,278	△ 40	99.9%	△ 759	98.8%
運送費、保管料 Transportation and storage	8,142	8,437	8,212	69	100.9%	△ 225	97.3%
広告宣伝費 Advertising	1,882	2,043	2,043	160	108.5%	―	100.0%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	33,844	33,791	33,319	△ 525	98.4%	△ 472	98.6%
研究開発費 Research and development	382	404	399	16	104.2%	△ 5	98.8%
管理費、その他 Other, net	11,890	11,662	11,605	△ 285	97.6%	△ 57	99.5%
販売費及び一般管理費 SG&A expenses	56,142	56,337	55,578	△ 564	99.0%	△ 759	98.7%
営業利益(△:損失) Operating income(Δ:loss)	4,175	4,700	4,700	524	112.6%	―	100.0%
営業外収益 Non-operating income	236	213	219	△ 17	92.5%	6	102.8%
営業外費用 Non-operating expenses	299	378	405	105	135.4%	27	107.1%
経常利益(△:損失) Ordinary income(Δ:loss)	4,113	4,535	4,514	400	109.7%	△ 21	99.5%
特別利益 Extraordinary gain	299	―	0	△ 299	0.0%	0	―
特別損失 Extraordinary loss	564	158	202	△ 362	35.8%	44	127.8%
税金等調整前当期純利益(△:損失) Income before income taxes(Δ:loss)	3,848	4,377	4,312	463	112.0%	△ 65	98.5%
法人税、住民税及び事業税 Current income taxes	1,343	1,399	1,382	66	105.0%	△ 17	98.8%
法人税等調整額 Deferred income taxes	△ 27						
当期純利益(△:損失) Net income(Δ:loss)	2,532	2,978	2,930	397	115.7%	△ 48	98.4%

設備投資額(有形・無形) Capital expenditures	5,520	1,937	1,937	△ 3,583	35.1%	―	100.0%
減価償却費(有形・無形) Depreciation and Amortization	2,736	2,886	2,851	114	104.2%	△ 35	98.8%

③ 宝酒造インターナショナルグループ :Takara Shuzo International Group

（百万円 :Millions of Yen）

	2020年3月期 FY2020	2021年3月期 FY2020_Apr. 1, 2020 - Mar. 31, 2021		対前期 Change from FY2020		対11/10予想 Change from forecast announced Nov. 2020	
	実績(a) Actual (a)	11/10予想(b) Forecast announced Nov. 2020 (b)	2/10予想(c) Forecast announced Feb. 2021 (c)	増減(c-a) Change (c-a)	比(c/a) % (c/a)	増減(c-b) Change (c-b)	比(c/b) % (c/b)
海外酒類事業 Overseas Alcoholic beverages business	11,365	9,860	10,293	△ 1,072	90.6%	433	104.4%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	73,371	59,917	60,380	△ 12,991	82.3%	463	100.8%
その他 Other	204	56	57	△ 147	27.8%	1	101.8%
連結消去 Elimination	△ 2,175	△ 1,459	△ 1,457	718	―	2	―
売上高 Net sales	82,765	68,374	69,273	△ 13,492	83.7%	899	101.3%
売上原価 Cost of sales	58,882	48,328	48,728	△ 10,154	82.8%	400	100.8%
売上総利益 Gross profit	23,883	20,046	20,545	△ 3,338	86.0%	499	102.5%
運送費、保管料 Transportation and storage	2,656	2,219	2,285	△ 371	86.0%	66	103.0%
広告宣伝費 Advertising	84	82	84	△ 0	99.6%	2	102.4%
販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p.	756	597	536	△ 220	70.9%	△ 61	89.8%
管理費、その他 Other, net	16,854	16,896	16,708	△ 146	99.1%	△ 188	98.9%
販売費及び一般管理費 SG&A expenses	20,351	19,794	19,613	△ 738	96.4%	△ 181	99.1%
海外酒類事業 Overseas Alcoholic beverages business	2,339	1,956	2,213	△ 126	94.6%	257	113.1%
海外日本食材卸事業 Japanese food wholesale business in overseas markets	2,735	△ 161	252	△ 2,483	9.2%	413	―
その他 Other	△ 853	△ 1,070	△ 1,078	△ 224	―	△ 8	―
連結消去 Elimination	△ 689	△ 473	△ 455	234	―	18	―
営業利益(△:損失) Operating income(Δ:loss)	3,532	252	932	△ 2,600	26.4%	680	369.8%
営業外収益 Non-operating income	320	137	142	△ 178	44.4%	5	103.6%
営業外費用 Non-operating expenses	344	194	281	△ 63	81.6%	87	144.8%
経常利益(△:損失) Ordinary income(Δ:loss)	3,507	195	793	△ 2,714	22.6%	598	406.7%
特別利益 Extraordinary gain	41	4	10	△ 31	24.0%	6	250.0%
特別損失 Extraordinary loss	23	37	38	14	163.9%	1	102.7%
税金等調整前当期純利益(△:損失) Income before income taxes(Δ:loss)	3,526	162	765	△ 2,761	21.7%	603	472.2%
法人税等 Current income taxes, etc.	1,157	85	211	△ 939	18.3%	126	248.2%
法人税等調整額 Deferred income taxes	△ 7						
当期純利益(△:損失) Net income(Δ:loss)	2,375	77	554	△ 1,821	23.3%	477	719.5%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	205	△ 262	△ 163	△ 368	―	99	―
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	2,170	339	717	△ 1,453	33.0%	378	211.5%
設備投資額(有形・無形) Capital expenditures	2,696	2,631	2,631	△ 65	97.6%	―	100.0%
減価償却費(有形・無形) Depreciation and Amortization	1,434	1,170	1,345	△ 89	93.8%	175	115.0%
のれん償却額 Amortization of goodwill	350	370	380	29	108.3%	10	102.7%

④ タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

	2020年3月期 FY2020	2021年3月期 FY2020_Apr. 1, 2020 - Mar. 31, 2021		対前期 Change from FY2020		対11/10予想 Change from forecast announced Nov. 2020	
	実績(a) Actual (a)	11/10予想(b) Forecast announced Nov. 2020 (b)	2/10予想(c) Forecast announced Feb. 2021 (c)	増減(c-a) Change (c-a)	比(c/a) % (c/a)	増減(c-b) Change (c-b)	比(c/b) % (c/b)
研究用試薬 Research reagents	24,840	29,940	34,014	9,173	136.9%	4,073	113.6%
理化学機器 Scientific instruments	1,242	1,454	1,844	601	148.4%	389	126.8%
受託サービス Contracted service	6,186	8,539	9,087	2,901	146.9%	548	106.4%
遺伝子医療 Gene Therapy	2,295	865	253	△ 2,042	11.0%	△ 611	29.3%
売上高 Net sales	34,565	40,800	45,200	10,634	130.8%	4,400	110.8%
売上原価 Cost of sales	13,459	15,420	15,526	2,067	115.4%	105	100.7%
売上総利益 Gross profit	21,105	25,379	29,673	8,567	140.6%	4,294	116.9%
運送費、保管料 Transportation and storage	492	693	725	232	147.3%	32	104.6%
広告宣伝費 Advertising	73	58	57	△ 15	78.4%	△ 1	97.4%
販売促進費 Sales promotion	579	724	726	147	125.5%	2	100.4%
研究開発費 Research and development	3,869	5,173	5,288	1,418	136.7%	115	102.2%
管理費、その他 Other, net	9,816	10,729	10,875	1,058	110.8%	145	101.4%
販売費及び一般管理費 SG&A expenses	14,830	17,379	17,673	2,842	119.2%	294	101.7%
営業利益(△:損失) Operating income(Δ:loss)	6,274	8,000	12,000	5,725	191.2%	4,000	150.0%
営業外収益 Non-operating income	316	307	328	11	103.7%	20	106.6%
営業外費用 Non-operating expenses	243	207	228	△ 15	93.7%	20	109.8%
経常利益(△:損失) Ordinary income(Δ:loss)	6,347	8,100	12,100	5,752	190.6%	4,000	149.4%
特別利益 Extraordinary income	0	1	76	76	16,399.5%	75	6418.3%
特別損失 Extraordinary loss	914	679	743	△ 170	81.3%	64	109.5%
税金等調整前当期純利益(△:損失) Income before income taxes(Δ:loss)	5,433	7,421	11,433	5,999	210.4%	4,011	154.0%
法人税、住民税及び事業税 Current income taxes	1,544	2,394	3,598	1,996	224.6%	1,203	150.2%
法人税等調整額 Deferred income taxes	57						
当期純利益(△:損失) Net income(Δ:loss)	3,831	5,027	7,834	4,002	204.5%	2,807	155.9%
非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss)	11	27	34	22	292.0%	7	128.5%
親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss)	3,819	5,000	7,800	3,980	204.2%	2,800	156.0%
設備投資額(有形・無形) Capital expenditures	5,365	8,813	8,813	3,447	164.3%	―	100.0%
減価償却費(有形・無形) Depreciation and Amortization	2,921	3,305	3,236	315	110.8%	△ 68	97.9%
のれん償却額 Amortization of goodwill	496	486	486	△ 10	97.9%	△ 0	99.9%

(注)2021年3月期より、報告セグメントを単一セグメントに変更したため、2020年3月期の実績を組み替えて表示しております。

(注)「研究用試薬」の売上高には、当第3四半期連結会計期間に発売した対外診断用医薬品の売上高を含めております。

8. 2021年3月期 業績予想 参考資料 :Reference Data for the year ending March 31, 2021

① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

	2020年3月期 FY2020	2021年3月期 FY2020_Apr. 1, 2020 - Mar. 31, 2021	
	実績(a) Actual (a)	2/10予想(c) Forecast announced Feb. 2021 (c)	前期差 Change(c-a)
米ドル : US dollar	109.03	106.77	△ 2.26
ポンド: Pound	139.19	137.02	△ 2.17
ユーロ: Euro	122.03	121.88	△ 0.15
人民元: Yuan	15.77	15.48	△ 0.29
100ウォン: 100 Won	9.36	9.06	△ 0.30
インドルピー: Rupee	1.55	1.44	△ 0.11
ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona	11.53	11.63	0.10
ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar	79.93	77.43	△ 2.50
ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar	75.78	73.69	△ 2.09

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

	対前期 Change from FY2020
宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated-	△ 1,469
うち宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Net sales of Takara Shuzo International Group	△ 1,025
海外酒類事業 Overseas Alcoholic beverages business	△ 189
海外日本食材卸事業 Japanese food wholesale business in overseas markets	△ 861
その他 Other	―
連結消去 Elimination	25
うちタカラバイオグループ Net sales of Takara Bio Group	△ 448
研究用試薬 Research reagents	△ 414
理化学機器 Scientific instruments	△ 9
受託サービス Contracted service	△ 25
遺伝子医療 Gene Therapy	―

② 海外売上高比率 :Overseas sales ratio

(百万円 :Millions of Yen)

	2020年3月期通期実績 FY2020 Actual			2021年3月期通期予想 FY2021 Forecast		
	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio	売上高計 Net Sales	海外売上高 Overseas Sales	海外売上高比率 Overseas Sales Ratio
宝酒造 Takara Shuzo	153,141	―	―	152,788	―	―
宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group	82,765	82,372	99.5%	69,273	68,975	99.6%
タカラバイオグループ Takara Bio Group	34,565	19,760	57.2%	45,200	25,643	56.7%
その他および調整額 Other / Adjustment	10,719	―	―	9,739	―	―
宝ホールディングス(連結) Takara Holdings Inc. -Consolidated-	281,191	102,132	36.3%	277,000	94,619	34.2%

③ 宝酒造インターナショナルグループおよびタカラバイオグループの主要子会社の業績 :Financial Forecast of major subsidiaries

		2020年3月期通期実績 FY2020 Actual		2021年3月期通期予想 FY2021 Forecast	
		売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
米国宝酒造	千 US ドル :Thousands of US dollar	35,691	3,897	27,594	573
Takara Sake USA Inc.	百 万 円 :Millions of Yen	3,891	424	2,946	61
宝酒造食品	千 元 :Thousands of Yuan	57,258	4,867	44,014	1,292
Takara Shuzo Foods Co.,Ltd.	百 万 円 :Millions of Yen	902	76	681	20.0
トマーチン	千 ポ ン ド :Thousands of Pound	19,777	5,090	19,677	6,183
The Tomatin Distillery Co.,Ltd.	百 万 円 :Millions of Yen	2,752	708	2,696	847
ｴｲｼﾞ･ｲﾝﾀｰﾅｼｮﾅﾙ	千 US ドル :Thousands of US dollar	26,990	12,045	30,737	14,038
AGE INTERNATIONAL,INC.	百 万 円 :Millions of Yen	2,942	1,313	3,281	1,498
フーデックスグループ	千 ユ ー ロ :Thousands of Euro	179,814	16,096	161,075	11,639
FOODEX Group	百 万 円 :Millions of Yen	21,942	1,964	19,631	1,418
タザキフーズ	千 ポ ン ド :Thousands of Pound	46,099	1,656	40,987	1,540
TAZAKI FOODS LTD.	百 万 円 :Millions of Yen	6,416	230	5,616	211
ミューチャルトレーディング	千 US ドル :Thousands of US dollar	369,212	6,224	283,283	△ 16,857
Mutual Trading Co., Inc.	百 万 円 :Millions of Yen	40,255	678	30,246	△ 1,799
ニッポンフード	千 AUS ドル :Thousands of Australian dollar	57,180	△ 2,363	51,524	2,648
Nippon Food Supplies Company Pty Ltd	百 万 円 :Millions of Yen	4,333	△ 179	3,796	195
東京共同貿易 Tokyo Mutual Trading Co., Ltd.	百 万 円 :Millions of Yen	2,848	205	6,577	227
ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S. （連結）	千 ユ ー ロ :Thousands of Euro	25,324	1,184	52,061	9,101
Takara Bio Europe S.A.S. Consolidated	百 万 円 :Millions of Yen	3,090	144	6,345	1,109
宝生物工程(大連)	千 元 :Thousands of Yuan	220,491	67,392	343,768	159,774
Takara Biotechnology (Dalian) Co.,Ltd.	百 万 円 :Millions of Yen	3,477	1,062	5,321	2,473
宝日医生物技術(北京)	千 元 :Thousands of Yuan	404,484	77,614	537,673	97,751
Takara Biomedical Technology(Beijing) Co., Ltd.	百 万 円 :Millions of Yen	6,378	1,223	8,323	1,513
ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ	百 万 ウ ォ ン :Millions of Won	10,841	1,709	12,605	2,123
Takara Korea Biomedical Inc.	百 万 円 :Millions of Yen	1,014	159	1,142	192
タカラバイオDSSインド	千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee	235,890	19,389	460,020	63,790
DSS Takara Bio India Private Limited	百 万 円 :Millions of Yen	365	30	662	91
タカラバイオUSA	千 US ドル :Thousands of US dollar	102,922	14,912	102,679	5,379
Takara Bio USA, Inc.	百 万 円 :Millions of Yen	11,221	1,625	10,963	574

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

（百万円 :Millions of Yen）

	対前期増減 Change from FY2020	
	増減計 Total Change	(参考)原価コストダウン Reference :Cost reduction
売上総利益 計 Gross profit	△ 40	+241

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結)要約損益計算書(p.8)における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.8)

	2020年3月期通期実績 FY2020 Actual		2021年3月期通期予想 FY2021 Forecast	
	売上高 Net Sales	営業利益 Operating income(Δ:loss)	売上高 Net Sales	営業利益 Operating income(Δ:loss)
物流事業 Transportation	14,243	598	13,730	552
宝ホールディングス(不動産事業) Takara Holdings (Real estate business)	528	442	506	419
その他 Other	17,029	977	14,997	784
「その他」計 Total "Other"	31,801	2,018	29,234	1,756